The investigational three-drug regimen, which produced hepatitis C cure rates of 97 percent, is an oral interferon-free therapy. Previously, the typical treatment for hepatitis C after a liver transplant was an interferon-based therapy, usually given for 48 weeks. It had a much lower response rate, had a risk of organ rejection and was poorly tolerated because of the immunosuppressants required to prevent rejection. The new oral regimen -- ABT-450, ombitasvir and dasabuvir (with or without ribavirin) -- produces significantly fewer side effects and is prescribed for 24 weeks.
Med-Chemist : "Quintessential Medicinal Chemistry"
Showing posts with label ombitasvir and dasabuvir (with or without ribavirin). Show all posts
Showing posts with label ombitasvir and dasabuvir (with or without ribavirin). Show all posts
Thursday, November 20, 2014
Subscribe to:
Posts (Atom)